Anupam Rama
Stock Analyst at JP Morgan
(3.69)
# 795
Out of 5,038 analysts
279
Total ratings
47.56%
Success rate
8.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Overweight | $74 → $79 | $28.60 | +176.22% | 11 | Oct 23, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $30 → $44 | $14.67 | +199.93% | 8 | Oct 21, 2025 | |
| REPL Replimune Group | Upgrades: Neutral | $11 | $8.75 | +25.79% | 12 | Oct 20, 2025 | |
| RAPT RAPT Therapeutics | Upgrades: Overweight | $13 → $55 | $29.95 | +83.64% | 9 | Oct 20, 2025 | |
| CDTX Cidara Therapeutics | Initiates: Overweight | $200 | $97.97 | +104.14% | 1 | Oct 10, 2025 | |
| MAZE Maze Therapeutics | Maintains: Overweight | $27 → $37 | $30.12 | +22.86% | 2 | Sep 29, 2025 | |
| CAMP Camp4 Therapeutics | Downgrades: Neutral | n/a | $3.40 | - | 1 | Sep 16, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $55 → $70 | $53.37 | +31.16% | 11 | Sep 3, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $13 | $5.55 | +134.23% | 8 | Aug 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $20 → $17 | $12.06 | +40.96% | 5 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $29 | $7.94 | +265.24% | 5 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $15 | $18.21 | -17.63% | 7 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $53 | $29.77 | +78.03% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $37 | $28.70 | +28.92% | 17 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $145 | $142.90 | +1.47% | 18 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $21.68 | +10.70% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $33.64 | +137.81% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $33.83 | +245.85% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $15.10 | +171.52% | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $28.05 | +81.82% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $34 | $7.19 | +372.88% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $27.53 | +59.83% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $8.36 | +103.35% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $38.41 | +4.14% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $90.72 | +37.79% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.08 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.58 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.34 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.95 | +340.68% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $6.21 | +1,350.44% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $14.63 | +1,608.82% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.94 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $55.43 | +4.64% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $14.14 | -15.13% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $6.14 | +502.61% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $73.33 | -25.00% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $2.24 | +1,150.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $41.93 | +28.79% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.72 | +6,150.00% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $16.46 | +64.03% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $460.09 | -70.22% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $8.88 | +440.54% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.05 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $270 | $3.79 | +7,024.01% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.28 | +2,243.75% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $66.30 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.61 | - | 2 | Jul 21, 2017 |
IDEAYA Biosciences
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $28.60
Upside: +176.22%
Cogent Biosciences
Oct 21, 2025
Maintains: Overweight
Price Target: $30 → $44
Current: $14.67
Upside: +199.93%
Replimune Group
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $8.75
Upside: +25.79%
RAPT Therapeutics
Oct 20, 2025
Upgrades: Overweight
Price Target: $13 → $55
Current: $29.95
Upside: +83.64%
Cidara Therapeutics
Oct 10, 2025
Initiates: Overweight
Price Target: $200
Current: $97.97
Upside: +104.14%
Maze Therapeutics
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $30.12
Upside: +22.86%
Camp4 Therapeutics
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.40
Upside: -
BridgeBio Pharma
Sep 3, 2025
Maintains: Overweight
Price Target: $55 → $70
Current: $53.37
Upside: +31.16%
Solid Biosciences
Aug 14, 2025
Maintains: Overweight
Price Target: $15 → $13
Current: $5.55
Upside: +134.23%
ORIC Pharmaceuticals
Aug 14, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $12.06
Upside: +40.96%
Aug 14, 2025
Maintains: Overweight
Price Target: $28 → $29
Current: $7.94
Upside: +265.24%
Aug 14, 2025
Upgrades: Neutral
Price Target: $15
Current: $18.21
Upside: -17.63%
Aug 7, 2025
Maintains: Overweight
Price Target: $56 → $53
Current: $29.77
Upside: +78.03%
Aug 4, 2025
Maintains: Overweight
Price Target: $35 → $37
Current: $28.70
Upside: +28.92%
Jul 31, 2025
Maintains: Neutral
Price Target: $140 → $145
Current: $142.90
Upside: +1.47%
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $21.68
Upside: +10.70%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $33.64
Upside: +137.81%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $33.83
Upside: +245.85%
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $15.10
Upside: +171.52%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $28.05
Upside: +81.82%
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $7.19
Upside: +372.88%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $27.53
Upside: +59.83%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $8.36
Upside: +103.35%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $38.41
Upside: +4.14%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $90.72
Upside: +37.79%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $3.08
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.58
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $3.34
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.95
Upside: +340.68%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $6.21
Upside: +1,350.44%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $14.63
Upside: +1,608.82%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.94
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $55.43
Upside: +4.64%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $14.14
Upside: -15.13%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $6.14
Upside: +502.61%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $73.33
Upside: -25.00%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $2.24
Upside: +1,150.00%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $41.93
Upside: +28.79%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.72
Upside: +6,150.00%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $16.46
Upside: +64.03%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $460.09
Upside: -70.22%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $8.88
Upside: +440.54%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.05
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $225 → $270
Current: $3.79
Upside: +7,024.01%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.28
Upside: +2,243.75%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $66.30
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -